BCIM
ALXN

British Columbia Investment Management’s Alexion Pharmaceuticals ALXN Stock Holding History

British Columbia Investment Management’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-40,845
Closed -$7.5M – 849
2021
Q2 		$7.5M Buy
40,845
+4,882
+14% +$838K 0.05% 338
2021
Q1 		$5.5M Sell
35,963
-1,154
-3% -$179K 0.04% 366
2020
Q4 		$5.8M Sell
37,117
-1,182
-3% -$152K 0.04% 344
2020
Q3 		$4.38M Buy
38,299
+2,820
+8% +$304K 0.04% 370
2020
Q2 		$3.98M Buy
35,479
+11,273
+47% +$1.2M 0.04% 356
2020
Q1 		$2.17M Sell
24,206
-28,631
-54% -$2.81M 0.04% 347
2019
Q4 		$5.71M Buy
52,837
+22,156
+72% +$2.37M 0.04% 335
2019
Q3 		$3M Sell
30,681
-71,685
-70% -$8.08M 0.03% 465
2019
Q2 		$13.4M Buy
102,366
+4,328
+4% +$558K 0.12% 174
2019
Q1 		$13.3M Buy
98,038
+41,906
+75% +$5.21M 0.12% 171
2018
Q4 		$5.46M Buy
56,132
+7,235
+15% +$855K 0.05% 392
2018
Q3 		$6.8M Sell
48,897
-50,936
-51% -$6.39M 0.07% 320
2018
Q2 		$12.4M Buy
99,833
+15,785
+19% +$1.84M 0.11% 214
2018
Q1 		$9.37M Sell
84,048
-19,206
-19% -$2.3M 0.07% 318
2017
Q4 		$12.3M Buy
103,254
+8,997
+10% +$1.1M 0.09% 269
2017
Q3 		$13.2M Sell
94,257
-69,384
-42% -$9.43M 0.1% 241
2017
Q2 		$19.9M Sell
163,641
-40,232
-20% -$4.68M 0.16% 164
2017
Q1 		$24.7M Buy
203,873
+52,600
+35% +$6.78M 0.2% 120
2016
Q4 		$18.5M Buy
151,273
+16,492
+12% +$2.02M 0.16% 146
2016
Q3 		$16.5M Sell
134,781
-16,255
-11% -$2.09M 0.17% 144
2016
Q2 		$17.6M Buy
151,036
+1,046
+0.7% +$148K 0.15% 149
2016
Q1 		$20.9M Buy
149,990
+26,692
+22% +$3.92M 0.2% 121
2015
Q4 		$23.5M Sell
123,298
-28,769
-19% -$5.03M 0.23% 105
2015
Q3 		$23.8M Sell
152,067
-1,699
-1% -$310K 0.24% 101
2015
Q2 		$27.8M Buy
153,766
+12,999
+9% +$2.24M 0.26% 93
2015
Q1 		$24.4M Buy
140,767
+11,297
+9% +$2.04M 0.22% 117
2014
Q4 		$24M Buy
129,470
+4,532
+4% +$840K 0.2% 130
2014
Q3 		$20.7M Sell
124,938
-8,058
-6% -$1.32M 0.17% 146
2014
Q2 		$20.8M Sell
132,996
-4,293
-3% -$678K 0.17% 156
2014
Q1 		$20.9M Sell
137,289
-12,053
-8% -$1.92M 0.18% 150
2013
Q4 		$19.8M Buy
149,342
+35,778
+32% +$4.29M 0.16% 166
2013
Q3 		$13.2M Sell
113,564
-4,911
-4% -$539K 0.11% 221
2013
Q2 		$10.9M Buy
+118,475
New +$11.4M 0.09% 262

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $379M AUM 28.34% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.96B AUM 48.96% 1-Year Est. Return

British Columbia Investment Management's ALXN Position: Q3 2021 in Review

British Columbia Investment Management sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 40,845 shares — an estimated $7.5M sold.

British Columbia Investment Management first reported a position in ALXN in Q2 2013 and held it in 33 quarters. The position peaked at $27.8M in Q2 2015. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • British Columbia Investment Management reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • British Columbia Investment Management sold 40,845 Alexion Pharmaceuticals shares in Q3 2021, an estimated $7.5M.
  • British Columbia Investment Management first reported a position in Alexion Pharmaceuticals in Q2 2013 and held it in 33 quarters.
  • British Columbia Investment Management's Alexion Pharmaceuticals position peaked at $27.8M in Q2 2015.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on British Columbia Investment Management's 13F filing for Q3 2021, filed 12 Nov 2021.